. Author manuscript; available in PMC: 2017 Nov 1.

Published in final edited form as: Am J Obstet Gynecol. 2016 Jul 11;215(5):622.e1–622.e8. doi: 10.1016/j.ajog.2016.07.013

Table 2.

Current pregnancy factors by 17OHP-C responder status.

	17OHP - C non-responder (n=159)	17OHP - C responder (n=595)	P - value
Pre-pregnancy body mass index (kg/m²), mean +/− SD	26.0 +/− 6.6	26.7 +/− 6.7	0.284
Smoked during pregnancy, n (%)	26 (16.4)	94 (15.8)	0.865
One or more episode(s) of vaginal bleeding or diagnosis of clinical abruption, n (%)	18 (11.3)	19 (3.2)	<0.001
Bacterial vaginosis, n(%)	11 (23.4)	43 (33.1)	0.217
Trichomonas during pregnancy, n(%)	2 (4.3)	14 (10.8)	0.182
Gonorrhea and/or chlamydia infection during pregnancy, n(%)	11 (6.9)	13 (2.2)	0.003
Short cervix <2.50cm^*, n (%)	4 (6.8)	9 (3.0)	0.243
Cervical cerclage, n(%)	4 (2.5)	12 (2.0)	0.698
Randomized to receive omega3 capsules, n(%)	81 (50.9)	301 (50.6)	0.937
Received antenatal corticosteroids, n(%)	43 (27.0)	110 (18.5)	0.017
Received tocolysis, n(%)	52 (32.7)	107 (18.0)	<0.001
Median number of hospital admissions for tocolysis (IQR)	0 (0, 1)	0 (0, 0)	<0.001
Male fetus	92 (57.9)	285 (47.9)	0.026

among 355 women with at least one transvaginal cervical length assessment

Abbreviations = 17OHP-C: 17-alpha hydroxyprogesterone caproate; IQR: interquartile range (25th and 75th percentiles)